β2-glycoprotein I and protection from anti-SSA/Ro60- associated cardiac manifestations of neonatal lupus

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 520-526

  Reed, Joanne H ^a   Clancy, Robert M ^a   Purcell, Anthony W ^b   Kim, Mimi Y ^c   Gordon, Tom P ^d   Buyon, Jill P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G; PLASMIN; RO ANTIBODY;

APOPTOSIS; ARTICLE; BINDING COMPETITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS CIRCULATION; FLOW CYTOMETRY; HEART DISEASE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEWBORN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; SYSTEMIC LUPUS ERYTHEMATOSUS; UMBILICAL CORD BLOOD;

ANTIBODIES, ANTINUCLEAR; APOPTOSIS; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BINDING, COMPETITIVE; CELLS, CULTURED; FEMALE; FETAL BLOOD; FIBRINOLYSIN; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYOCYTES, CARDIAC; PROTEIN BINDING; RIBONUCLEOPROTEINS; RNA, SMALL CYTOPLASMIC;

EID: 79960414998     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100122     Document Type: Article

References (33)

1. Buyon, J. P., and D. M. Friedman. 2011. Neonatal lupus. In Systemic Lupus Erythematosus, 2nd Ed., R. G. Lahita, G. Tsokos, J. P. Buyon, and T. Koike, eds. Academic Press, San Diego, CA, p. 541-567.
2. Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179: 1317-1330.
3. Miranda, M. E., C. E. Tseng, W. Rashbaum, R. L. Ochs, C. A. Casiano, F. Di Donato, E. K. Chan, and J. P. Buyon. 1998. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J. Immunol. 161: 5061-5069.
4. Clancy, R. M., P. J. Neufing, P. Zheng, M. O'Mahony, F. Nimmerjahn, T. P. Gordon, and J. P. Buyon. 2006. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J. Clin. Invest. 116: 2413-2422.
5. Clancy, R. M., R. P. Kapur, Y. Molad, A. D. Askanase, and J. P. Buyon. 2004. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum. 50: 173-182.
6. Reed, J. H., B. Giannakopoulos, M. W. Jackson, S. A. Krilis, and T. P. Gordon. 2009. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum. 60: 860-869.
7. Clancy, R. M. 2009. When the levee doesn't break: a novel role of beta2-glycoprotein I to protect against congenital heart block. Arthritis Rheum. 60: 636-638.
8. Schwarzenbacher, R., K. Zeth, K. Diederichs, A. Gries, G. M. Kostner, P. Laggner, and R. Prassl. 1999. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 18: 6228-6239. (Pubitemid 29533227)
9. Cvirn, G., S. Gallistl, M. Koestenberger, J. Kutschera, U. Ferstl, J. Kellner, G. Jurgens, and A. Gries. 2007. Effects of beta2-glycoprotein-I on platelet aggregation in cord versus adult whole blood. Platelets 18: 24-28.
10. Miyakis, S., B. Giannakopoulos, and S. A. Krilis. 2004. Beta 2 glycoprotein I: function in health and disease. Thromb. Res. 114: 335-346.
11. Ohkura, N., Y. Hagihara, T. Yoshimura, Y. Goto, and H. Kato. 1998. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 91: 4173-4179. (Pubitemid 28261980)
12. Horbach, D. A., E. van Oort, T. Lisman, J. C. Meijers, R. H. Derksen, and P. G. de Groot. 1999. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb. Haemost. 81: 87-95.
13. Briassouli, P., E. V. Komissarova, R. M. Clancy, and J. P. Buyon. 2010. Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: implications in the pathogenesis of congenital heart block. Circ. Res. 107: 374-387.
14. Buyon, J. P., R. Hiebert, J. Copel, J. Craft, D. Friedman, M. Katholi, L. A. Lee, T. T. Provost, M. Reichlin, L. Rider, et al. 1998. Autoimmune- associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J. Am. Coll. Cardiol. 31: 1658-1666.
15. Friedman, D. M., M. Y. Kim, J. A. Copel, C. Davis, C. K. Phoon, J. S. Glickstein, J. P. Buyon; PRIDE Investigators. 2008. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 117: 485-493.
16. Miranda-Carús, M. E., M. Boutjdir, C.-E. Tseng, F. DiDonato, E. K. Chan, and J. P. Buyon. 1998. Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in a murine model. J. Immunol. 161: 5886-5892.
17. Reed, J. H., P. J. Neufing, M.W. Jackson, R. M. Clancy, P. J.Macardle, J. P. Buyon, and T. P. Gordon. 2007. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin. Exp. Immunol. 148: 153-160.
18. Sheng, Y. H., J. G. Hanly, S. W. Reddel, S. Kouts, J. Guerin, T. Koike, K. Ichikawa, A. Sturgess, and S. A. Krilis. 2001. Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. Clin. Exp. Immunol. 124: 502-508.
19. Guerin, J., Y. H. Sheng, S. W. Reddel, G. M. Iverson, M. G. Chapman, and S. A. Krilis. 2002. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein: elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J. Biol. Chem. 277: 2644-2649.
20. McNally, T., I. J. Mackie, D. A. Isenberg, and S. J. Machin. 1993. Immunoelectrophoresis and ELISA techniques for assay of plasma beta 2 glycoprotein-1 and the influence of plasma lipids. Thromb. Res. 72: 275-286.
21. Gordon, T. P., G. Kinoshita, D. Cavill, C. L. Keech, A. D. Farris, K. Kaufman, J. McCluskey, and A. W. Purcell. 2002. Restricted specificity of intermolecular spreading to endogenous La (SS-B) and 60 kDa Ro (SS-A) in experimental autoimmunity. Scand. J. Immunol. 56: 168-173.
22. Reed, J. H., N. L. Dudek, S. E. Osborne, K. M. Kaufman, M. W. Jackson, A. W. Purcell, and T. P. Gordon. 2010. Reactivity with dichotomous determinants of Ro 60 stratifies autoantibody responses in lupus and primary Sjögren's syndrome. Arthritis Rheum. 62: 1448-1456.
23. Schwede, T., J. Kopp, N. Guex, and M. C. Peitsch. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31: 3381-3385.
24. Hanayama, R., M. Tanaka, K. Miwa, A. Shinohara, A. Iwamatsu, and S. Nagata. 2002. Identification of a factor that links apoptotic cells to phagocytes. Nature 417: 182-187. (Pubitemid 34506799)
25. Wu, Y., S. Singh, M. M. Georgescu, and R. B. Birge. 2005. A role for Mer tyrosine kinase in alphavbeta5 integrin-mediated phagocytosis of apoptotic cells. J. Cell Sci. 118: 539-553.
26. Lin, F., R. Murphy, B. White, J. Kelly, C. Feighery, R. Doyle, S. Pittock, J. Moroney, O. Smith, W. Livingstone, et al. 2006. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus 15: 87-93. (Pubitemid 43345333)
27. Reed, J. H., M. W. Jackson, and T. P. Gordon. 2008. A B cell apotope of Ro 60 in systemic lupus erythematosus. Arthritis Rheum. 58: 1125-1129.
28. Tran, H. B., P. J. Macardle, J. Hiscock, D. Cavill, J. Bradley, J. P. Buyon, and T. P. Gordon. 2002. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum. 46: 1572-1579.
29. Neufing, P. J., R. M. Clancy, M. W. Jackson, H. B. Tran, J. P. Buyon, and T. P. Gordon. 2005. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum. 52: 3934-3942.
30. Sodin-Semrl, S., and B. Rozman. 2007. Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels. Autoimmun. Rev. 6: 547-552.
31. Mehdi, H., S. Manzi, P. Desai, Q. Chen, C. Nestlerode, F. Bontempo, S. C. Strom, R. Zarnegar, and M. I. Kamboh. 2003. A functional polymorphism at the transcriptional initiation site in beta2-glycoprotein I (apolipoprotein H) associated with reduced gene expression and lower plasma levels of beta2- glycoprotein I. Eur. J. Biochem. 270: 230-238.
32. Briasouli, P., E. V. Komissarova, D. Alvarez, J. P. Buyon, and R. M. Clancy. 2009. Role of the urokinase plasminogen receptor in mediating impaired apoptotic cardiomyocyte clearance by anti-SSA/Ro-SSB/La antibodies in the pathogenesis of congenital heart block. Arthritis Rheum. 60: S1962.
33. Gordon, P., M. A. Khamashta, E. Rosenthal, J. M. Simpson, G. Sharland, A. Brucato, F. Franceschini, K. De Bosschere, L. Meheus, P. L. Meroni, et al. 2004. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J. Rheumatol. 31: 2480-2487. (Pubitemid 39603101)